Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Corthera
company
About
Corthera is engaged in acquiring, developing and commercializing therapies for illnesses in the acute care setting.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $23M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2002
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Corthera Inc., formerly BAS Medical, is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in a global, phase 2/3 clinical trial for acute decompensated heart failure. Corthera has worldwide rights to develop and commercialize relaxin.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$23M
Corthera has raised a total of
$23M
in funding over 2 rounds. Their latest funding was raised on
Dec 20, 2007 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 20, 2007 | Series C | $23M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Corthera is funded by 1 investors.
Caxton Advantage Life Sciences Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Caxton Advantage Life Sciences Fund
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
